Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Pinealon vs Other Neuroprotective Peptides: Half-Life Comparison

Pinealon 6–8 hours Twice daily (every 10–12 hours) Renal filtration + aminopeptidase degradation Minimal. Effects via gene expression, not accumulation Short half-life requires strict twice-daily protocol but extended transcriptional effects justify the freque

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Pinealon
  • 6–8 hours
  • Twice daily (every 10–12 hours)
  • Renal filtration + aminopeptidase degradation
  • Minimal. Effects via gene expression, not accumulation
  • Short half-life requires strict twice-daily protocol but extended transcriptional effects justify the frequency
  • Semax
  • 4–6 hours (intranasal)
  • 2–3 times daily
  • Enzymatic degradation in nasal mucosa and serum
  • Minimal blood-brain barrier penetration
  • Extremely short half-life but direct CNS delivery via olfactory pathway bypasses systemic circulation entirely
  • Selank
  • 3–5 hours
  • Rapid peptidase cleavage of Met-enkephalin-like sequence
  • None. Functions via transient receptor binding
  • Anxiolytic effects outlast plasma presence, similar to pinealon's gene expression mechanism
  • Cerebrolysin
  • 2–3 hours (active peptide fraction)
  • Daily IV infusion over 30–60 minutes
  • Hepatic metabolism of heterogeneous peptide mixture
  • Unknown. Proprietary blend composition
  • Complex pharmacokinetics due to multiple active components with varying half-lives
  • P21 (Noopept metabolite)
  • 25–30 minutes (prodrug), 60–90 minutes (active)
  • Hepatic conversion then rapid renal clearance
  • Cycloprolylglycine (active metabolite) shows extended neural effects
  • Ultra-short parent compound half-life but active metabolite sustains effects. Dosing based on metabolite kinetics
  • BPC-157
  • 4–6 hours (estimated, limited human data)
  • Once or twice daily
  • Gastric stability but rapid systemic clearance
  • Possible tissue depot effect in injury sites
  • Longer dosing intervals tolerated despite short half-life. May involve localized peptide reservoirs
  • The comparison reveals a consistent pattern across neuroprotective peptides: plasma half-life poorly predicts dosing requirements when the mechanism involves gene expression modulation rather than direct receptor agonism. Pinealon's 6–8 hour half-life falls mid-range but the twice-daily protocol remains non-negotiable because the compound functions as a transcriptional regulator, not a sustained signaling molecule.

Related resources

More comparisons